{
    "organizations": [],
    "uuid": "031828d75046c45c1a38c4df36d5a92a2aefb005",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-gilead-natco-and-teva-requested-fd/brief-gilead-natco-and-teva-requested-fda-permission-to-make-generic-version-of-sovaldi-sec-filing-idUSFWN1QH0QD",
    "ord_in_thread": 0,
    "title": "BRIEF-Gilead: Natco And Teva Requested FDA Permission To Make Generic Version Of Sovaldi - SEC Filing",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - Gilead Sciences Inc:\n* GILEAD SCIENCES INC SAYS IN FEBRUARY 2018, CO RECEIVED NOTICES FROM NATCO PHARMA LIMITED AND TEVA PHARMA - SEC FILING\n* GILEAD SCIENCES INC - NATCO PHARMA LIMITED,TEVA EACH SUBMITTED ANDA TO FDA REQUESTING PERMISSION TO MANUFACTURE AND MARKET GENERIC VERSION OF SOVALDI\n* GILEAD SCIENCES - TEVA ALLEGES THAT NINE PATENTS ASSOCIATED WITH SOFOSBUVIR INVALID, UNENFORCEABLE AND/OR WILL NOT BE INFRINGED BY TEVA’S MANUFACTURE\n* GILEAD SCIENCES-NATCO PHARMA ALLEGES THAT TWO PATENTS ASSOCIATED WITH SOFOSBUVIR INVALID,UNENFORCEABLE AND/OR WILL NOT BE INFRINGED BY NATCO’S MANUFACTURE Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)\n ",
    "published": "2018-02-27T19:44:00.000+02:00",
    "crawled": "2018-02-28T12:47:21.028+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "gilead",
        "science",
        "inc",
        "gilead",
        "science",
        "inc",
        "say",
        "february",
        "co",
        "received",
        "notice",
        "natco",
        "pharma",
        "limited",
        "teva",
        "pharma",
        "sec",
        "filing",
        "gilead",
        "science",
        "inc",
        "natco",
        "pharma",
        "limited",
        "teva",
        "submitted",
        "anda",
        "fda",
        "requesting",
        "permission",
        "manufacture",
        "market",
        "generic",
        "version",
        "sovaldi",
        "gilead",
        "science",
        "teva",
        "alleges",
        "nine",
        "patent",
        "associated",
        "sofosbuvir",
        "invalid",
        "unenforceable",
        "infringed",
        "teva",
        "manufacture",
        "gilead",
        "pharma",
        "alleges",
        "two",
        "patent",
        "associated",
        "sofosbuvir",
        "invalid",
        "unenforceable",
        "infringed",
        "natco",
        "manufacture",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "bengaluru",
        "newsroom"
    ]
}